Experimental drug boosts treatment response for hard-to-treat ovarian cancer
Patients with advanced, hard-to-treat ovarian cancer have responded well to treatment with a drug called IACS-6274 when combined with the targeted therapy bevacizumab and paclitaxel chemotherapy.
Read original article on The Medical News →